Lokahi Therapeutics has submitted a clinical protocol for the regulatory review of LT-100, a biologic drug candidate targeting osteoarthritis knee pain. The company is preparing clinical operations and advancing manufacturing readiness while building trial infrastructure, with study initiation targeted pending regulatory feedback.
LT-100 would be administered via a once-weekly subcutaneous injection, a significant simplification from a prior regimen requiring 15 weekly intradermal injections. Lokahi operates out of Rutherford, New Jersey, and La Jolla, California.
Lokahi Therapeutics is a wholly owned subsidiary of Glucotrack (NASDAQ: GCTK), which completed a business combination with the company on July 14, 2026. Glucotrack Technologies, the parent's other subsidiary, focuses on continuous blood glucose monitoring technology.
CEO Erik Emerson said the company's strategy is to identify and acquire clinical-stage assets, execute clinical and regulatory activities to generate data, and pursue strategic licensing and partnership opportunities. Lokahi intends to discover therapeutic assets, advance them through process enhancements, and monetize them before the completion of registration trials.
The company's AI-driven discovery platform, ai2, works with more than 14 university partners to screen over 12,000 late-stage pharmaceutical programs that have been decommissioned or deprioritized by their original developers. In its first year, ai2 identified over 45 assets meeting initial screening criteria, and preliminary business development discussions are underway for certain opportunities. The platform also provides pharmaceutical industry exposure to student participants in the evaluation process. An early-stage project within the ai2 accelerator framework is named Qare.
The announcement was published Wednesday, September 23, 2026.
